These trials completed more than 12 months ago and should have reported results.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
|Status||Trial ID||Title||Completion date||Category|
|Reported results||2005-000941-12||Phase III randomised, placebo controlled study of sorafenib in repeated cycles of 21 days in combination with paclitaxel/carboplatin chemotherapy in subjects with unresectable stage III or stage IV me...||2009-01-08||due-trials|
|Listed as ongoing, but also has a completion date and reported results||2009-016839-35||A Randomized, Multicenter, Phase 3 Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects with Relapsed Multiple Myeloma||2017-12-05||bad-data|
|Reported results||2009-016840-38||A Randomized, Open-label, Phase 3 Study of Carfilzomib vs Best Supportive Care in Subjects with Relapsed and Refractory Multiple Myeloma||2015-09-04||due-trials|
|Reported results||2012-000128-16||A Randomized, Open-label, Phase 3 Study of Carfilzomib Plus Dexamethasone Versus Bortezomib Plus Dexamethasone in Patients With Relapsed Multiple Myeloma||2018-02-05||due-trials|
|Listed as ongoing, but also has a completion date and reported results||2012-005283-97||A Randomized, Open-label Phase 3 Study of Carfilzomib, Melphalan, and Prednisone versus Bortezomib, Melphalan, and Prednisone in Transplant ineligible Patients with Newly Diagnosed Multiple Myeloma||2016-11-04||bad-data|
|Exempt||2013-001169-18||Phase 1b/2, Multicenter, Open-label Study of Oprozomib and||2019-06-25||not-yet-due|
|Exempt, with results||2013-002125-27||Phase 1b/2, Multicenter, Open-label Study of Oprozomib, Melphalan, and Prednisone in Transplant Ineligible Patients with Newly Diagnosed Multiple Myeloma||2015-08-31||not-yet-due|
|Exempt, with results||2013-002597-44||Phase 1b/2, Multicenter, Open-label Study of Carfilzomib, Carboplatin, and Etoposide in Subjects with Previously Untreated Extensive-stage Small-cell Lung Cancer||2017-05-04||not-yet-due|
|Other||2014-001633-84||Phase 1b/2 Study of Carfilzomib in Combination with Dexamethasone, Mitoxantrone, PEG-asparaginase, and Vincristine (UK R3 Induction Backbone) in Children with Relapsed or Refractory Acute Lymphoblasti...||not-yet-due|
|Listed as ongoing, but also has a completion date and reported results||2014-005325-12||A Randomized, Open-label, Phase 3 Study in Subjects with Relapsed and Refractory Multiple Myeloma Receiving Carfilzomib in Combination with Dexamethasone, Comparing Once-weekly versus Twice-weekly Car...||2019-01-07||bad-data|